(2R,3R,4S,5R)-2-(6-(Ethylamino)-2-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | 765299-59-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,4S,5R)-2-(6-(Ethylamino)-2-(4-(4-methoxyphenyl)-1H-pyrazol-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
• 英文别名: (2R,3R,4S,5R)-2-[6-(ethylamino)-2-[4-(4-methoxyphenyl)pyrazol-1-yl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 765299-59-0
• 化学式: C₂₂H₂₅N₇O₅
• 分子量: 467.5
• InChiKey: RWRIXGUSCOWTAI-QTQZEZTPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  153
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• Adenosine A3 receptor agonists
  申请人：——

  公开号：US20040116376A1

  公开（公告）日：2004-06-17

  Disclosed are novel compounds that are A 3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.

  本发明涉及一种新型化合物，它们是A3腺苷受体激动剂，可用于治疗各种疾病状态，包括癌症、心脏缺血、白细胞减少症和中性粒细胞减少症。
• Adenosine receptor A3 agonists
  申请人：——

  公开号：US20030078232A1

  公开（公告）日：2003-04-24

  Disclosed are novel compounds that are A 3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.

  本发明揭示了一种新型化合物，它们是A3腺苷受体激动剂，可用于治疗各种疾病状态，包括癌症、心脏缺血、白细胞减少症和中性粒细胞减少症。
• ADENOSINE A3 RECEPTOR AGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1414837A1

  公开（公告）日：2004-05-06
• US7262176B2
  申请人：——

  公开号：US7262176B2

  公开（公告）日：2007-08-28
• [EN] ADENOSINE A3 RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR ADENOSINE A3
  申请人：CV THERAPEUTICS INC

  公开号：WO2003014137A1

  公开（公告）日：2003-02-20

  Disclosed are novel compounds of the Formula I that are A3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia. Formula (I) wherein: R1 is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X is a covalent bond or optionally substituted alkylene; R1 is R4 Z-Y-C=C- or optionally substituted pyrazolyl: in which Y is optionally substituted alkylene, Z is oxygen, sulfur or NH-, and R4 is optionally substituted aryl or optionally substituted heteroaryl; and R3 is hydroxymethyl or C(0)-NR5R6; in which R?5 and R6¿ are independently hydrogen or lower alkyl.